바이오스펙테이터

by Euna Lee

Pancreatic cancer, glioblastoma, and Alzheimer’s disease are some of the most intractable diseases in the world. But there has been zero successful development of new drugs to cure Alzheimer’s disease. One company is challenging such intractable diseases – ‘BeyondBio’, which was founded in June 2013 in the ‘BioVenture’ Town’ in Daejeon Metropolitan City.

CEO Min of BeyondBio commented, “BEY1107 and BEY2153 have demonstrated excellent efficacy and BBB transmissivity at the non-clinical stage. We intend to develop innovative and differentiated new drugs of a new mechanism aiming for the cure of intractable diseases requiring drugs. If we are able to cure pancreatic cancer and brain tumors, then our development for new drugs will expand to include diseases for which medicine is efficacious, such as colon cancer and breast cancer.” CEO Min’s career has included LG Chem, LG Life Science (LG Biomedical Institute), and Hanall BioPharma. (as head of the Research Institute), wherein he developed diverse kinds of new drugs.

‘BeyondBio’ successfully invited an investment of 15.5 billion KRW for Series C last April through capital increase, with consideration of an allotment to the third party. The company intends to enter the KOSDAQ market in the second half of next year, through the listing system supporting technologies of special cases.

◇ CDK1 Inhibitor ‘BEY1107’ are there reliable therapeutic effects for pancreatic cancer or glioblastoma?

The leading pipeline of ‘BEY1107’ currently promoted by ‘BeyondBio’ is the CDK1 inhibitor that controls cell cycle. Currently, efforts are concentrated on circumventing cancer transference, recurrence, and drug tolerance of existing drugs intended for the treatment of pancreatic cancer and brain tumors. BEY1107 employs a mechanism that suppresses the proliferation of cancer cells by blocking progress towards the G2/M stage of the cell cycle.... <계속>